Nurix Therapeutics, Inc. (NRIX)
AI stock analysis · as of Jun 8, 2026
Loading microstructure…
Nurix Therapeutics is a clinical-stage protein degrader biotech whose lead asset, bexobrutideg (BTK degrader), is in a pivotal Phase 2 accelerated-approval trial in triple-refractory CLL with early 83% ORR data. The company has now layered a transformative Roche partnership (~$2.3–3B) on top of existing Gilead/Sanofi/Pfizer collaborations ($482M received, up to $6.1B in milestones). The core question: does the platform validation and pivotal readout path justify a ~$1.6B market cap against persistent ~$260M annual cash burn and binary clinical risk?
valuationExpensive on traditional metrics (P/S 22x, P/B 3.3x, negative EV/EBITDA) but rational for a de-risked pivotal-stage degrader with Roche validation; valuation hinges entirely on bexobrutideg probability-of-success and milestone NPV, not current financials.
This analysis is from Jun 8, 2026. Want the latest on NRIX, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Bexobrutideg Phase 2 DAYBreak (started Oct 2025) is an accelerated-approval path in triple-refractory CLL with 83% ORR in Phase 1 — a high-unmet-need population where competing covalent/noncovalent BTKi options have failed
- · Roche deal (~$2.3–3B) announced June 2026 validates the degrader platform and expands bexobrutideg into MS and chronic urticaria, addressing a cited ~$41B TAM beyond oncology
- · Diversified partner base — Gilead, Sanofi, Pfizer, now Roche — with $6.1B+ potential milestones; Sanofi licensed two programs in 2025 already proving pipeline productivity
- · Revenue grew 54% YoY to $84M in FY2025, demonstrating accelerating collaboration cash inflows that partially offset burn
- · Elevated short interest (18.2% of float, 21.6 days to cover) on top of fresh positive catalyst sets up potential squeeze dynamics; analyst consensus 'strong buy' with $30 target (~95% upside) and 17 analysts covering
- · DEL-AI platform is multi-asset optionality (NX-1607 IO program with MSS-CRC activity, BRAF pan-mutant degrader) — not solely dependent on bexobrutideg
Bear case
- · Cash burn of $263M FCF against $247M cash on hand implies <12 months runway absent milestone receipts or dilution; ATM offerings are an active financing tool
- · Phase 2 is single-arm accelerated approval — no comparator means any ORR/durability shortfall, resistance emergence, or safety signal could kill the lead asset; FY net loss widened 37% to $264M
- · Zelebrudomide precedent: prior manufacturing-related partial clinical hold paused enrollment for over a year — repeat risk for bexobrutideg at scale is real
- · BTK competition is entrenched: ~$10.6B in 2024 BTKi sales across ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib; degraders must prove differentiated benefit in less-refractory lines to capture meaningful share
- · Stock already had a 24–70% gap-up on Roche news; much of the platform validation premium is now in the price (P/S 22x, P/B 3.3x)
- · Insiders own only 1.1% — limited skin in the game; institutional ownership >100% reported is data anomaly worth diligence
Catalysts
- · Bexobrutideg DAYBreak CLL-201 Phase 2 interim/registrational data updates through 2026
- · Bexobrutideg autoimmune IND filing planned 2026 (separate from oncology program)
- · Multiple partner milestone events expected in 2026 across Gilead/Sanofi/Pfizer/Roche — each triggers non-dilutive cash
- · NX-1607 Phase 1b cohort expansion in solid tumors (MSS-CRC) planned 2026
- · Next earnings July 9, 2026 — first print incorporating Roche deal economics and updated cash runway
- · Short squeeze potential: 18.2% short float + 21.6 days-to-cover into positive data catalysts
Key risks
- · Pivotal Phase 2 single-arm trial failure or insufficient durability would eliminate most of the lead asset value
- · Manufacturing/CMC issues triggering a clinical hold (precedent with zelebrudomide)
- · Dilution risk via ATM offerings if milestones slip and burn continues at ~$260M/yr
- · Partner termination or restructuring of any of the four collaborations would materially impair revenue and pipeline
- · Competitive entry of other BTK degraders or improved noncovalent inhibitors compressing addressable market
What to watch
- · July 9, 2026 earnings: Roche deal upfront recognition, updated cash runway, FY2026 burn guidance
- · Any bexobrutideg DAYBreak Phase 2 enrollment or interim data commentary
- · Short interest trend post-Roche — squeeze setup with 21.6 days-to-cover
- · 52-week levels: support at $8.19 low, resistance at $22.50 high; current $15.50 mid-range
- · Form 4 filings post-Roche deal for additional insider activity beyond the pre-deal CLO sale
- · Milestone announcements from Gilead, Sanofi, Pfizer in 2026 as non-dilutive funding signals
Key metrics
Price target rationale
Base $24 assumes a partial re-rate on continued bexobrutideg Phase 2 progress and Roche deal milestones, applying ~30x forward P/S on growing collaboration revenue plus risk-adjusted pipeline NPV. Bull $38 reflects positive pivotal data update and additional milestone triggers, in line with Street high. Bear $8 reflects clinical setback, manufacturing hold, or dilutive raise that returns shares to 52-week low.
On Wall Street's view (mixed): The $30 consensus target (~95% upside) is directionally reasonable given Roche deal economics and pivotal-stage optionality, but it likely understates near-term dilution risk and binary trial outcomes; I see fair value modestly below consensus in a base case.
Latest filing (10-K)
Nurix is a protein degrader biotech with a potentially pivotal BTK degrader (bexobrutideg) now in Phase 2 for triple-refractory CLL showing 83% ORR, backed by $482M in partner funding from Gilead, Sanofi, and Pfizer and $6.1B in potential milestones, but burning cash with no approved products.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) medicines for cancer and inflammatory diseases. It generates revenue through collaboration and license agreements with Gilead, Sanofi, and Pfizer, having received $482 million in non-dilutive funding to date, while retaining full rights to its wholly owned pipeline. The company has no product sales revenue and operates at a loss, funding operations through partner payments and equity issuances.
What the news says · bullish
The dominant storyline for NRIX on June 8, 2026 is a landmark partnership with Roche for its BTK degrader bexobrutideg, valued at approximately $2.3–$3 billion, targeting blood cancers, MS, and chronic hives — a combined addressable market cited at ~$41 billion. The deal triggered a massive premarket surge of nearly 70%, with intraday gains settling in the 24–38% range across various reports, confirming strong investor enthusiasm. This is a classic biotech catalyst event: a major pharma validation of Nurix's targeted protein degradation platform with significant upfront and milestone economics. Minor headwinds include a routine insider sale by the CLO in early June (pre-deal, likely 10b5-1 plan) and one anomalous Blockonomi headline describing the stock as 'dropping' on the news, which appears to be an outlier or error given the weight of contrary evidence. Coverage is robust on the deal day, though prior weeks showed thin, mixed sentiment around valuation.
This analysis is from Jun 8, 2026. Markets move. Get the current read on NRIX and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.